X0306 4 2019-01-14 0 0001346302 XERIS PHARMACEUTICALS INC XERS 0001744027 PRESTRELSKI STEVEN C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 0 1 0 0 Chief Scientific Officer Common Stock 2019-01-14 4 S 0 7700 17.2025 D 469324 D Common Stock 2019-07-11 4 S 0 9962 12.037 D 459362 D Common Stock 2019-07-11 4 S 0 38 12.70 D 459324 D Common Stock 2019-10-11 4 S 0 10000 7.9746 D 449324 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. $17.2025 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.05 to $18.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. $12.0370 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.59 to $12.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. $7.9746 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.73 to $8.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. /s/Beth Hecht, as Attorney-in-Fact 2019-10-16